See more : FJ Next Holdings Co., Ltd. (8935.T) Income Statement Analysis – Financial Results
Complete financial analysis of Athira Pharma, Inc. (ATHA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Athira Pharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- NorAm Drilling AS (NORAM.OL) Income Statement Analysis – Financial Results
- Lee Pharmaceuticals, Inc. (LPHM) Income Statement Analysis – Financial Results
- Bangkok Aviation Fuel Services Public Company Limited (BAFS.BK) Income Statement Analysis – Financial Results
- Beaglee Inc. (3981.T) Income Statement Analysis – Financial Results
- Sprouts Farmers Market, Inc. (SFM) Income Statement Analysis – Financial Results
Athira Pharma, Inc. (ATHA)
About Athira Pharma, Inc.
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 969.00K | 1.05M | 479.00K | 2.00M | 0.00 | 0.00 |
| Gross Profit | -969.00K | -1.05M | -479.00K | -2.00M | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 93.79M | 61.46M | 42.79M | 13.29M | 3.79M | 3.59M |
| General & Administrative | 33.30M | 32.55M | 21.23M | 6.71M | 1.66M | 1.42M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 33.30M | 32.55M | 21.23M | 6.71M | 1.66M | 1.42M |
| Other Expenses | -1.63M | -5.16M | -8.84M | -1.32M | -754.00K | -164.00K |
| Operating Expenses | 125.47M | 88.86M | 55.19M | 18.67M | 4.70M | 5.01M |
| Cost & Expenses | 125.47M | 88.86M | 55.19M | 18.67M | 4.70M | 5.01M |
| Interest Income | 7.64M | 3.22M | 337.00K | 124.00K | 51.00K | 85.00K |
| Interest Expense | 0.00 | 24.32M | 3.00K | 367.00K | 346.00K | 9.00K |
| Depreciation & Amortization | 969.00K | 1.05M | 479.00K | 2.00M | 2.00K | 5.01M |
| EBITDA | -116.70M | -94.59M | -54.37M | -19.01M | -4.82M | -79.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -125.47M | -104.02M | -64.02M | -20.00M | -5.45M | -5.01M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 7.79M | 8.38M | 9.17M | 40.00K | 288.00K | -88.00K |
| Income Before Tax | -117.67M | -95.64M | -54.85M | -19.96M | -5.16M | -5.10M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -8.38M | -479.00K | -1.32M | -459.00K | -76.00K |
| Net Income | -117.67M | -87.26M | -54.37M | -18.63M | -4.70M | -5.10M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.10 | -2.31 | -1.47 | -0.57 | -0.14 | -0.82 |
| EPS Diluted | -3.09 | -2.31 | -1.47 | -0.57 | -0.14 | -0.82 |
| Weighted Avg Shares Out | 38.02M | 37.73M | 36.92M | 32.49M | 32.62M | 6.19M |
| Weighted Avg Shares Out (Dil) | 38.02M | 37.73M | 36.92M | 32.49M | 32.62M | 6.19M |
Athira Pharma Announces Formation of Scientific Advisory Board Comprised of Renowned Leaders in Neurology Research
BOTHELL, Wash., June 07, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the formation of a Scientific Advisory Board (SAB)...
ATHIRA PHARMA INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Athira Pharma, Inc. - ATHA
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Athira Pharma, Inc. (NasdaqGS: ATHA). On June 17,...
ATHIRA PHARMA INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Athira Pharma, Inc. - ATHA
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Athira Pharma, Inc. (NasdaqGS: ATHA). On June 17,...
ATHIRA ALERT: Bragar Eagel & Squire, P.C. Is Investigating Athira Pharma, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Athira Pharma, Inc. (NASDAQ: ATHA) on behalf of long-term stockholders following a class action complaint that was filed against Athira on...
ATHIRA ALERT: Bragar Eagel & Squire, P.C. Is Investigating Athira Pharma, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Athira Pharma, Inc. (NASDAQ: ATHA) on behalf of long-term stockholders following a class action complaint that was filed against Athira...
Shareholders Approve the Election of All Three Athira Director Nominees at 2022 Annual Meeting
BOTHELL, Wash., May 19, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced, based on the preliminary vote count provided by...
Athira Issues Statement in Response to Richard A. Kayne's Suspension of His Proxy Contest
Athira Board Unanimously Recommends Shareholders Vote “FOR” its Highly Qualified Nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE proxy card
Ric Kayne Suspends Campaign to Elect Himself and George Bickerstaff to Athira Pharma Board of Directors
NEW YORK--(BUSINESS WIRE)--Richard A. (Ric) Kayne, who together with his affiliates beneficially owns approximately 4.8% of the outstanding shares of common stock of Athira Pharma, Inc. (NASDAQ: ATHA) (“Athira” or the “Company”), today issued the following letter to Athira shareholders....
Ric Kayne Issues Letter to Athira Shareholders Highlighting Need for Immediate Change to Athira Board
NEW YORK--(BUSINESS WIRE)--Richard A. (Ric) Kayne, who together with his affiliates beneficially owns approximately 4.8% of the outstanding shares of common stock of Athira Pharma, Inc. (NASDAQ: ATHA) (“Athira” or the “Company”), today issued a letter to Athira shareholders outlining...
Ric Kayne Issues Letter to Athira Shareholders Highlighting Need for Immediate Change to Athira Board
NEW YORK--(BUSINESS WIRE)--Richard A. (Ric) Kayne, who together with his affiliates beneficially owns approximately 4.8% of the outstanding shares of common stock of Athira Pharma, Inc. (NASDAQ: ATHA) (“Athira” or the “Company”), today issued a letter to Athira shareholders outlining...
Source: https://incomestatements.info
Category: Stock Reports